Skip to Main Content

If any pharma CEO is still intoxicated by the idea of a megamerger, the rough Monday Bristol-Myers Squibb (BMY) is having could be an antidote.

The company announced that in order to assuage the Federal Trade Commission’s concerns about its $74 billion purchase of rival Celgene (CELG), it will seek to sell Celgene’s blockbuster psoriasis treatment Otezla.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!